
The Centers for Disease Control and Prevention reports that there has been a significant decline in the rates of new acute hepatitis infections over the last 10 years in the United States. This decline is due in part to hepatitis A and B vaccination programs.
The American Liver Foundation finds this news promising, but is urging people to remember that chronic hepatitis B and C affect more than 5 million Americans and that hepatitis C rates are actually on the rise. There are vaccines for hepatitis A and B but not for C. Hepatitis C is the most common blood-borne infection in the United States, and almost 4 million Americans are infected with it.
Acute or short-term infections more commonly occur with hepatitis A and B and are less likely to cause long-term illness. However, those exposed to hepatitis C have a 70%–80% chronic infection rate. A 2002 study showed the medical costs for people with hepatitis C are $15 billion annually. The study predicts that if current rates do not drop significantly, the projected direct and indirect health care costs for the period 2010–2019 will be $85 billion. (The Advocate)
These comments are reproduced as written by visitors to this Web site. They have not been edited for content, grammar, or spelling. The viewpoints appearing here are those of the writer, and do not necessarily reflect the opinion or views of advocate.com, The Advocate, or its affiliates.
Be the first to comment on this story.
If you would like to submit a comment for posting, please fill out the form above.
All comments submitted via this form are subject to posting or publication. (To send a private letter to an Advocate editor or writer, please use the e-mail button at the top of the page, or use snail mail.) If you would like your comment considered for publication in The Advocate magazine, please include your full name, your city of residence, and a phone number where you can be reached during business hours so that we can confirm your identity. Your e-mail address and telephone number are strictly confidential and will not be shared or used for any purpose other than to contact you about your comment.
See the Contact page for sending comments for reasons other than responding to Advocate editorial and news stories.
Please note that comments sent by fax or snail mail are unlikely to be posted, although they will be considered for publication along with all letters received via e-mail or via this Web page. Comments that chiefly concern Advocate.com content will be considered for posting only on the Web site. The Advocate reserves the right to edit submitted comments for grammar, spelling, obscenities, or libel; we will, however, do our best to preserve the original comment's style and intent. Comments considered for publication in The Advocate magazine may also be edited for length.